AMAT
52
3
ESS
40
-5
EMC
47
11
PCG
74
2
MCHP
47
-8
FSLR
73
15
CAH
63
3
CRM
70
18
CL
58
2
HRL
23
-12
TGNA
53
-3
DRI
66
2
GM
85
2
MMM
56
2
AMG
77
3
CTAS
40
-2
F
59
3
MTCH
59
9
RIG
40
2
TJX
53
-9
AMAT
52
3
ESS
40
-5
EMC
47
11
PCG
74
2
MCHP
47
-8
FSLR
73
15
CAH
63
3
CRM
70
18
CL
58
2
HRL
23
-12
TGNA
53
-3
DRI
66
2
GM
85
2
MMM
56
2
AMG
77
3
CTAS
40
-2
F
59
3
MTCH
59
9
RIG
40
2
TJX
53
-9
Financhill
Back

Mineralys Therapeutics, Inc. 10K Form

Sell
39

MLYS
Mineralys Therapeutics, Inc.

Last Price:
$36.85
Seasonality Move:
41.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MLYS News And Ratings

See the #1 stock for the next 7 days that we like better than MLYS

MLYS Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-28.9M
Price / Cash Flow: 0
Annual Sales: $7.30
Price / Book: 5.06

Profitability

EPS (TTM): -2.95810
Net Income (TTM): $-171.4M
Gross Margin: $-43K
Return on Equity: -51.62%
Return on Assets: -48.55%

Mineralys Therapeutics, Inc. Earnings Forecast

Key Mineralys Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 5 years have been positive in 0 years.

Mineralys Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MLYS
Website: mineralystx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 25.5
Quick Ratio: 25.24

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MLYS Technical Analysis vs Fundamental Analysis

Sell
39
Mineralys Therapeutics, Inc. (MLYS) is a Sell

Is Mineralys Therapeutics, Inc. a Buy or a Sell?